3/16
08:43 am
onc
BeOne Medicines (ONC) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $290.00 price target on the stock.
Low
Report
BeOne Medicines (ONC) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $290.00 price target on the stock.
3/3
08:24 pm
onc
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]
Low
Report
BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion [Yahoo! Finance]
2/27
01:11 pm
onc
BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.
Low
Report
BeOne Medicines (ONC) had its price target raised by Truist Financial Corporation from $400.00 to $412.00. They now have a "buy" rating on the stock.
2/27
10:58 am
onc
BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.
Low
Report
BeOne Medicines (ONC) had its price target raised by Guggenheim from $400.00 to $410.00. They now have a "buy" rating on the stock.
2/27
10:17 am
onc
BeOne Medicines (ONC) had its price target raised by Barclays PLC from $394.00 to $405.00. They now have an "overweight" rating on the stock.
Low
Report
BeOne Medicines (ONC) had its price target raised by Barclays PLC from $394.00 to $405.00. They now have an "overweight" rating on the stock.
2/26
05:03 pm
onc
BeOne Medicines (ONC) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
BeOne Medicines (ONC) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/26
06:00 am
onc
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
Medium
Report
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
2/17
06:00 am
onc
BeOne Medicines to Present at Upcoming Investor Conferences
Low
Report
BeOne Medicines to Present at Upcoming Investor Conferences
2/11
06:00 am
onc
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
Low
Report
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
2/4
06:09 am
onc
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/30
02:18 am
onc
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 [Yahoo! Finance]
Medium
Report
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 [Yahoo! Finance]
1/13
06:00 am
onc
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
1/12
07:17 am
onc
BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.
Low
Report
BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.
1/8
08:42 am
onc
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/6
01:30 pm
onc
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
Low
Report
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA